Join the Merkel Cell Carcinoma group to help and get support from people like you.
Merkel Cell Carcinoma News
Related terms: cutaneous APUDoma, Primary Neuroendocrine Carcinoma of the Skin, trabecular carcinoma of the skin
AACR: Pretrained Machine Learning Models Help Diagnose Nonmelanoma Skin Cancer
TUESDAY, April 29, 2025 – Leveraging whole slide embedding from pretrained foundation models (FMs) improves nonmelanoma skin cancer (NMSC) diagnosis, according to a study presented at the annual...
Many U.S. Adults Still Have Misconceptions About Skin Cancer Risk
WEDNESDAY, March 26, 2025 – About two-thirds of U.S. adults report no sunburns in the past year, with significant associations seen between the number of sunburns and sociodemographic factors,...
Machine Learning Model Accurately Predicts Survival in Merkel Cell Cancer
WEDNESDAY, Jan. 15, 2025 – A machine learning model can make accurate survival predictions for Merkel cell carcinoma (MCC), according to a study published online Jan. 8 in npj Digital Medicine....
Teledermoscopy Accurate for Detecting Skin Cancers
WEDNESDAY, Nov. 20, 2024 – Teledermoscopy has high accuracy for detecting skin cancers, according to a research letter published online Nov. 9 in the Journal of the American Academy of Dermatology....
FDA Approves Zynyz (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 22, 2023-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz (retifanlimab-dlwr), a humanized monoclonal...
FDA Approves Keytruda (pembrolizumab) for the Treatment of Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) December 19, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
March 23, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic...